|
Mr. Atieh is Executive Vice President and Chief Financial Officer of OSI Pharmaceuticals. He previously served as Chair of the OSI Audit Committee and was a member of the Board from 2003 until 2005 when he assumed his current position.
Mr. Atieh was recently Group President of Dendrite International and was previously Senior Vice President and Chief Financial Officer at Dendrite. Having started his career as an audit manager at Arthur Young & Company (now Ernst & Young), Mr. Atieh joined Merck and Company and held a number of senior positions from 1981-1994 including Director of Accounting, Director of Investor Relations, Vice President Government Relations, Treasurer and Vice President of Public Affairs. Mr. Atieh then moved to the Merck-Medco Division of Merck where he held a number of positions including Senior Vice President of Sales and Business Development. Mr. Atieh subsequently served as Vice President and General Manager of Merck's Medicare business initiative in their U.S. Human Health Division.
Mr. Atieh is on the Board of Directors of ACE Limited (NYCE:ACE) where he serves as a member of the Audit Committee and Finance and Investment Committee. | 